<DOC>
	<DOC>NCT02717923</DOC>
	<brief_summary>This is a single arm, open-label clinical trial to evaluate the efficacy and safety of maintenance treatment with capecitabine plus cetuximab after first-line modified fluorouracil, leucovorin, and oxaliplatin(mFOLFOX6) plus cetuximab for patients with KRAS wild-type metastatic colorectal cancer.</brief_summary>
	<brief_title>A Single Arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Maintenance Treatment With Capecitabine Plus Cetuximab in Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>1. Subjects has been fully understand this research and volunteered to sign the consent form; 2. Histologically and/or cytologically diagnosed with KRAS wildtype metastatic metastatic colorectal cancer(Phase IV), any other histological type is excluded; 3. Subjects with stable disease or better after induction treatment with eight to twelve 2weekly cycles of mFOLFOX6; 4. ECOG Performance Status (ECOG PS) ≤1(01); 5. Evident measurable lesion(s) that meets the Response Evaluation Criteria in Solid Tumors (RECIST 1.1); 6. Expected survival＞16 weeks. 1. Subjects with presence of clinically detectable second primary malignant tumors at the enrollment, or other malignant tumors within the last 5 years (excluding adequately treated skin basal cell carcinoma or carcinoma in situ of cervix); 2. Clinical refractory diseases(including uncontrolled epilepsy),and affect survivor; 3. Central Nervous System (CNS) metastatic disease or prior cerebral metastasis; 4. Researchers think that the subjects exist any clinical or laboratory abnormalities or compliance issues and not suitable to participate in this clinical study.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>metastatic colorectal cancer</keyword>
	<keyword>maintenance treatment</keyword>
	<keyword>cetuximab</keyword>
</DOC>